Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma...
November 14, 2019 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Third Quarter 2019 Financial Results

TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update....
November 06, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. ...
October 31, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
August 13, 2019 07:15 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2019 Financial Results

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. ...
August 05, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13

TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
July 22, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit

TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
June 04, 2019 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International...
June 03, 2019 08:00 ET | Source: VBL Therapeutics

Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity

TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented...
June 03, 2019 08:00 ET | Source: VBL Therapeutics

VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer

VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03)CA-125 response (GCIG) was reported in 58% of evaluable...

keyboard_arrow_left Previous Page